



(51) International Patent Classification:

C07D 403/12 (2006.01) **C07D 413/10** (2006.01)
C07D 401/04 (2006.01) **C07D 417/10** (2006.01)
C07D 401/10 (2006.01) **C07D 417/12** (2006.01)
C07D 403/04 (2006.01) **C07D 249/12** (2006.01)
C07D 403/10 (2006.01) **A61K 31/4196** (2006.01)
C07D 405/12 (2006.01) **A61P 29/00** (2006.01)
C07D 409/14 (2006.01)

(21) International Application Number:

PCT/IB2013/054752

(22) International Filing Date:

10 June 2013 (10.06.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1733/MUM/2012	15 June 2012 (15.06.2012)	IN
61/668,146	5 July 2012 (05.07.2012)	US
3319/MUM/2012	19 November 2012 (19.11.2012)	IN
61/735,679	11 December 2012 (11.12.2012)	US
387/MUM/2013	8 February 2013 (08.02.2013)	IN
61/792,225	15 March 2013 (15.03.2013)	IN

(71) Applicant: **GLENMARK PHARMACEUTICALS S.A.**
[CH/CH]; Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds (CH).

(72) Inventors: **GHARAT, Laxmikant Atmaram**; Flat No-203
Tirupati Apartments, Pokhran road no - 2, Majiwada,
Thane (West), Maharashtra 400601 (IN). **MUTHUKA-**
MAN, Nagarajan; # 20, Malay Amman Kovil Street,

Kodumudi, Erode, Tamil Nadu 638151 (IN). **KHAIR-ATKAR-JOSHI, Neelima**; 101, Devprayag CHS, Bhakti Mandir Rd, Hari Niwas, Panchpakhadi, Thane (W), Maharashtra 400602 (IN). **KATTIGE, Vidya Ganapati**; 101, Eureka, Hiranandani Estate, Patlipada, Off Ghodbunder Road, Thane (W), Maharashtra 400607 (IN).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS



(57) Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mP-GES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.